A committee of the European Commission issued a positive opinion regarding Genzyme's application to produce and market Pompe disease drug Myozyme at a Belgian manufacturing plant. The European Commission will make a final decision based on the opinion of the Committee for Medicinal Products for Human Use.

Related Summaries